- Home
- ALUR vs BCTX Comparison
ALUR vs BCTX Comparison
Compare ALUR & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALUR
- BCTX
- Stock Information
- Founded
- ALUR 2009
- BCTX 2014
- Country
- ALUR United States
- BCTX Canada
- Employees
- ALUR N/A
- BCTX N/A
- Industry
- ALUR
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- ALUR
- BCTX Health Care
- Exchange
- ALUR Nasdaq
- BCTX Nasdaq
- Market Cap
- ALUR 16.8M
- BCTX 13.8M
- IPO Year
- ALUR N/A
- BCTX N/A
- Fundamental
- Price
- ALUR $2.14
- BCTX $8.09
- Analyst Decision
- ALUR Strong Buy
- BCTX Strong Buy
- Analyst Count
- ALUR 3
- BCTX 1
- Target Price
- ALUR $22.83
- BCTX $40.00
- AVG Volume (30 Days)
- ALUR 52.4K
- BCTX 79.3K
- Earning Date
- ALUR 11-12-2025
- BCTX 10-28-2025
- Dividend Yield
- ALUR N/A
- BCTX N/A
- EPS Growth
- ALUR N/A
- BCTX N/A
- EPS
- ALUR N/A
- BCTX N/A
- Revenue
- ALUR $19,917,000.00
- BCTX N/A
- Revenue This Year
- ALUR N/A
- BCTX N/A
- Revenue Next Year
- ALUR $168.27
- BCTX N/A
- P/E Ratio
- ALUR N/A
- BCTX N/A
- Revenue Growth
- ALUR N/A
- BCTX N/A
- 52 Week Low
- ALUR $1.98
- BCTX $6.00
- 52 Week High
- ALUR $20.00
- BCTX $214.50
- Technical
- Relative Strength Index (RSI)
- ALUR 40.16
- BCTX 44.99
- Support Level
- ALUR $2.10
- BCTX $7.66
- Resistance Level
- ALUR $2.22
- BCTX $8.20
- Average True Range (ATR)
- ALUR 0.11
- BCTX 0.62
- MACD
- ALUR 0.02
- BCTX 0.37
- Stochastic Oscillator
- ALUR 40.74
- BCTX 74.11
About ALUR Allurion Technologies Inc.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.